Elucidating novel disease mechanisms in severe asthma

Clinical and Translational Immunology

Volumn 5, Issue 7, 2016, Pages

  Kim, Richard Y ^a   Rae, Brittany ^a   Neal, Rachel ^a   Donovan, Chantal ^a   Pinkerton, James ^a   Balachandran, Lohis ^a   Starkey, Malcolm R ^a   Knight, Darryl A ^a   Horvat, Jay C ^a   Hansbro, Philip M ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85020191174     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/CTI.2016.37     Document Type: Review

References (121)

1. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2015. Available from http://www.ginasthma.org/.
2. Australian Bureau of Statistics. Australian Health Survey. Updated Results, 2011–12. Available from http://www.abs.gov.au/AUSSTATS/subscriber.nsf/log?openagent &43640do007_20112012.xls&4364.0.55.001&DataCubes&18DEF104A278854D CA257B820017A5DB&0&2011-12&07.06.2013&Latest.
3. World Health Organisation. Bronchial Asthma 2016. Available from http://www.who. int/mediacentre/factsheets/fs206/en/.
4. Hansbro PM, Kaiko GE, Foster PS. Cytokine/anti‐cytokine therapy–novel treatments for asthma? Br J Pharmacol 2011; 163: 81–95.
5. Hansbro PM, Scott GV, Essilfie A-T, Kim RY, Starkey MR, Nguyen DH et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 2013; 22: 49–69.
6. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2013; 43: 343–373.
7. Reddel H, Sawyer S, Everett P, Flood P, Peters M. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. Med J Aust 2015; 202: 492–496.
8. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131: 636–645.
9. Hallstrand TS, Hackett TL, Altemeier WA, Matute-Bello G, Hansbro PM, Knight DA. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol 2014; 151: 1–15.
10. Carroll N, Carello S, Cooke C, James A. Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996; 9: 709–715.
11. Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc 2003; 24: 79–83.
12. Roche W, Williams J, Beasley R, Holgate S. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 333: 520–524.
13. Wilson J, Li X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin Exp Allergy 1997; 27: 363–371.
14. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al. T-helper type 2–driven inflammation defines major subphenotypes of asthma. Am J Resp Crit Care Med 2009; 180: 388–395.
15. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–2466.
16. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329–1336.
17. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision‐making: how does the immune system decide to mount a helper T‐cell response? Immunol 2008; 123: 326–338.
18. Holt PG. Antigen presentation in the lung. Am J Resp Crit Care Med 2000; 162: S151–S156.
19. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul W. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986; 136: 4538–4541.
20. 4+ T cell–dependent late allergic airway responses. J Allergy Clin Immunol 2005; 115: 521–526.
21. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001; 107: 429–441.
22. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 2003; 21: 579–628.
23. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8: 218–230.
24. McKenzie A, Culpepper J, de Waal Malefyt R, Briere F, Punnonen J, Aversa G et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993; 90: 3735–3739.
25. Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261–2263.
26. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132: 567–574, e512.
27. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211–218.
28. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197–216.
29. 4+ T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 2010; 32: 692–702.
30. Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43: 1067–1076.
31. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 2011; 127: 153–160.
32. Bellini A, Marini M, Bianchetti L, Barczyk M, Schmidt M, Mattoli S. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol 2012; 5: 140–149.
33. Zhao J, Lloyd CM, Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. Mucosal Immunol 2013; 6: 335–346.
34. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Resp Crit Care Med 2013; 188: 1294–1302.
35. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7: 301ra129.
36. Bourdin A, Neveu D, Vachier I, Paganin F, Godard P, Chanez P. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007; 119: 1367–1374.
37. Bullens D, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx. Respir Res 2006; 7: 135.
38. Carmichael J, Paterson IC, Diaz P, Crompton G, Kay A, Grant I. Corticosteroid resistance in chronic asthma. BMJ 1981; 282: 1419–1422.
39. Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM. Inflammasomes in COPD and neutrophilic asthma. Thorax 2015; 70: 1199–1201.
40. Gibeon D, Batuwita K, Osmond M, Heaney LG, Brightling CE, Niven R et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013; 143: 406–414.
41. Hirst C, Calingaert B, Stanford R, Castellsague J. Use of long-acting β-agonists and inhaled steroids in asthma: meta-analysis of observational studies. J Asthma 2010; 47: 439–446.
42. Wang W, Li JJ, Foster PS, Hansbro PM, Yang M. Potential therapeutic targets for steroid-resistant asthma. Curr drug targets 2010; 11: 957–970.
43. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139: 359–370.
44. Keenan CR, Salem S, Fietz ER, Gualano RC, Stewart AG. Glucocorticoid-resistant asthma and novel anti-inflammatory drugs. Drug Discov Today 2012; 17: 1031–1038.
45. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte J-J et al. Increased glucocorticoid receptor β in airway cells of glucocorticoid-insensitive asthma. Am J Resp Crit Care Med 1999; 159: 1600–1604.
46. Preston J, Thorburn A, Starkey M, Beckett E, Horvat J, Wade M et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur Respir J 2011; 37: 53–64.
47. Preston JA, Essilfie A-T, Horvat JC, Wade MA, Beagley KW, Gibson PG et al. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine 2007; 25: 8154–8162.
48. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol 2012; 188: 4611–4620.
49. Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: from potential to therapy. Am J Resp Cell Mol Biol 2010; 43: 511–519.
50. Thorburn AN, O’Sullivan BJ, Thomas R, Kumar RK, Foster PS, Gibson PG et al. Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease. Thorax 2010; 65: 1053–1060.
51. Essilfie A-T, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70: 458–467.
52. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS ONE 2014; 9: e105609.
53. Calhoun WJ, Reed HE, Moest DR, Stevens CA. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis 1992; 145: 317–325.
54. Kanazawa H, Kurihara N, Hirata K, Takeda T. The role of free radicals in airway obstruction in asthmatic patients. Chest 1991; 100: 1319–1322.
55. Mabalirajan U, Dinda AK, Kumar S, Roshan R, Gupta P, Sharma SK et al. Mitochondrial structural changes and dysfunction are associated with experimental allergic asthma. J Immunol 2008; 181: 3540–3548.
56. Comhair S, Janocha A, Mavrakis L, Erzurum S, Xu W. Alteration of nitric oxide synthesis related to abnormal cellular bioenergetics in asthmatic airway epithelium. Am J Respir Crit Care Med 2010; 181: A1436.
57. Chodaczek G, Bacsi A, Dharajiya N, Sur S, Hazra TK, Boldogh I. Ragweed pollen-mediated IgE-independent release of biogenic amines from mast cells via induction of mitochondrial dysfunction. Mol Immunol 2009; 46: 2505–2514.
58. Jaffer OA, Carter AB, Sanders PN, Dibbern ME, Winters CJ, Murthy S et al. Mitochondrial-targeted antioxidant therapy decreases transforming growth factor-β–mediated collagen production in a murine asthma model. Am J Resp Cell Mol Biol 2015; 52: 106–115.
59. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets 2007; 11: 745–755.
60. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol 2011; 186: 1870–1879.
61. Pascoe S, Kanniess F, Bonner J, Lloyd P, Lowe P, Beier J. A monoclonal antibody to IL-1β attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Annu Congr Eur Resp Soc 2006; A752. http://www.ersnet.org/learnin-g_resources_player/abstract_print_06/files/51.pdf. Accessed 8 June 2016.
62. Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol 2015; 135: 379–385.
63. Nikota JK, Botelho FM, Bauer CM, Jordana M, Coyle AJ, Humbles AA et al. Differential expression and function of breast regression protein 39 (BRP-39) in murine models of subacute cigarette smoke exposure and allergic airway inflammation. Resp Res 2011; 12: 39.
64. Willart MA, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN et al. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012; 209: 1505–1517.
65. Bamberger CM, Bamberger A-M, De Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435.
66. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001; 98: 6865–6870.
67. Li JJ, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG et al. IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J Immunol 2010; 185: 4401–4409.
68. Suzuki Y, Maazi H, Sankaranarayanan I, Lam J, Khoo B, Soroosh P et al. Lack of autophagy induces steroid-resistant airway inflammation. J Allergy Clin Immunol 2015; 137: 1382–1389.e9.
69. Burgess JK, Boustany S, Moir LM, Weckmann M, Lau JY, Grafton K et al. Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. Am J Resp Crit Care Med 2010; 181: 106–115.
70. Grafton KT, Moir LM, Black JL, Hansbro NG, Hansbro PM, Burgess JK et al. LF-15 & T7, synthetic peptides derived from tumstatin, attenuate aspects of airway remodelling in a murine model of chronic OVA-induced allergic airway disease. PLoS ONE 2014; 9: e85655.
71. Black JL, Panettieri RA Jr, Banerjee A, Berger P. Airway smooth muscle in asthma: just a target for bronchodilation? Clin Chest Med 2012; 33: 543–558.
72. Khan MA. Inflammation signals airway smooth muscle cell proliferation in asthma pathogenesis. Multidiscip Respir Med 2013; 8: 11.
73. Sanderson MJ, Bai Y, Perez-Zoghbi J. Ca(2+) oscillations regulate contraction of intrapulmonary smooth muscle cells. Adv Exp Med Biol 2010; 661: 77–96.
74. Gunst S, Tang D. The contractile apparatus and mechanical properties of airway smooth muscle. Eur Respir J 2000; 15: 600–616.
75. 2+ handling and sensitivity in airway smooth muscle: emerging concepts for mechanistic understanding and therapeutic targeting. Pulm Pharmacol Ther 2014; 29: 108–120.
76. Cho Y, Kim TB, Lee TH, Moon KA, Lee J, Kim YK et al. Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor‐α‐dependent pathway. Clin Exp Allergy 2005; 35: 1625–1631.
77. Hahn DL, Schure A, Patel K, Childs T, Drizik E, Webley W. Chlamydia pneumoniaespecific IgE is prevalent in asthma and is associated with disease severity. PLoS ONE 2012; 7: e35945.
78. Hansbro PM, Beagley KW, Horvat JC, Gibson PG. Role of atypical bacterial infection of the lung in predisposition/protection of asthma. Pharmacol Ther 2004; 101: 193–210.
79. Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK et al. Neonatal chlamydial infection induces mixed T-cell responses that drive allergic airway disease. Am J Resp Crit Care Med 2007; 176: 556–564.
80. Horvat JC, Starkey MR, Kim RY, Beagley KW, Preston JA, Gibson PG et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. J Immunol 2010; 184: 4159–4169.
81. Horvat JC, Starkey MR, Kim RY, Phipps S, Gibson PG, Beagley KW et al. Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology. J Allergy Clin Immunol 2010; 125: 617–625.
82. Wark P, Johnston S, Simpson J, Hensley M, Gibson P. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J 2002; 20: 834–840.
83. Patel KK, Vicencio AG, Du Z, Tsirilakis K, Salva PS, Webley WC. Infectious Chlamydia pneumoniae is associated with elevated interleukin-8 and airway neutrophilia in children with refractory asthma. Pediatr Infect Dis J 2010; 29: 1093–1098.
84. Black P, Scicchitano R, Jenkins C, Blasi F, Allegra L, Wlodarczyk J et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15: 254–259.
85. Beagley K, Huston WM, Hansbro PM, Timms P. Chlamydial infection of immune cells: altered function and implications for disease. Crit Rev Immunol 2009; 29: 275–305.
86. Kaiko GE, Phipps S, Hickey DK, Lam CE, Hansbro PM, Foster PS et al. Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity. J Immunol 2008; 180: 2225–2232.
87. Wood LG, Simpson JL, Hansbro PM, Gibson PG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. Free Radic Res 2010; 44: 146–154.
88. Essilfie A-T, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012; 67: 588–599.
89. Essilfie A-T, Simpson JL, Horvat JC, Preston JA, Dunkley ML, Foster PS et al. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog 2011; 7: e1002244.
90. Hansbro NG, Horvat JC, Wark PA, Hansbro PM. Understanding the mechanisms of viral induced asthma: new therapeutic directions. Pharmacol Ther 2008; 117: 313–353.
91. Wark P, Johnston S, Moric I, Simpson J, Hensley M, Gibson P. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2001; 19: 68–75.
92. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354: 1998–2005.
93. Ito K, Herbert C, Siegle JS, Vuppusetty C, Hansbro N, Thomas PS et al. Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. Am J Resp Cell Mol Biol 2008; 39: 543–550.
94. Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM et al. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLoS Pathog 2011; 7: e1001339.
95. Foster PS, Plank M, Collison A, Tay HL, Kaiko GE, Li J et al. The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. Immunol Rev 2013; 253: 198–215.
96. Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie A-T et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog 2015; 11: e1004549.
97. Yang M, Kumar RK, Hansbro PM, Foster PS. Emerging roles of pulmonary macrophages in driving the development of severe asthma. J Leukoc Biol 2012; 91: 557–569.
98. Starkey M, Essilfie A, Horvat J, Kim R, Nguyen D, Beagley K et al. Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease. Mucosal Immunol 2013; 6: 569–579.
99. Starkey M, Nguyen D, Essilfie A, Kim R, Hatchwell L, Collison A et al. Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease. Mucosal Immunol 2014; 7: 478–488.
100. Starkey MR, Kim RY, Beckett EL, Schilter HC, Shim D, Essilfie A-T et al. Chlamydia muridarum lung infection in infants alters hematopoietic cells to promote allergic airway disease in mice. PLoS ONE 2012; 7: e42588.
101. Starkey MR, Nguyen DH, Brown AC, Essilfie A-T, Kim RY, Yagita H et al. PD-L1 promotes early-life Chlamydia respiratory infection-induced severe allergic airway disease. Am J Resp Cell Mol Biol 2015; 54: 493–503.
102. Li X, Hawkins GA, Ampleford EJ, Moore WC, Li H, Hastie AT et al. Genome-wide association study identifies T H 1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol 2013; 132: 313–320.
103. Wan Y, Shrine N, Artigas MS, Wain L, Blakey J, Moffatt M et al. Genome-wide association study to identify genetic determinants of severe asthma. Thorax 2012; 67: 762–768.
104. Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. J Allergy Clin Immunol 2015; 136: 874–884.
105. Yan X, Chu J-H, Gomez J, Koenigs M, Holm C, He X et al. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am J Resp Crit Care Med 2015; 191: 1116–1125.
106. 8+ T cells in patients with severe asthma. J Allergy Clin Immunol 2012; 129: 95–103.
107. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G et al. The adaptor ASC has extracellular and ‘prionoid’activities that propagate inflammation. Nat Immunol 2014; 15: 727–737.
108. Hsu AC, Parsons K, Barr I, Lowther S, Middleton D, Hansbro PM et al. Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection. PLoS ONE 2012; 7: e32947.
109. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183: 195–201.
110. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207.
111. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Resp Med 2015; 3: 355–366.
112. Bai Y, Krishnamoorthy N, Patel KR, Rosas I, Sanderson MJ, Ai X. Cryopreserved human precision-cut lung slices as a bioassay for live tissue banking: a viability study of bronchodilation with bitter-taste receptor agonists. Am J Resp Cell Mol Biol 2015; 54: 656–663.
113. Donovan C, Bailey SR, Tran J, Haitsma G, Ibrahim ZA, Foster SR et al. Rosiglitazone elicits in vitro relaxation in airways and precision cut lung slices from a mouse model of chronic allergic airways disease. Am J Physiol Lung Cell Mol Physiol 2015; 309: L1219–L1228.
114. Donovan C, Seow HJ, Royce SG, Bourke JE, Vlahos R. Alteration of airway reactivity and reduction of ryanodine receptor expression by cigarette smoke in mice. Am J Respir Cell Mol Biol 2015; 53: 471–478.
115. Starkey MR, Jarnicki AG, Essilfie A-T, Gellatly SL, Kim RY, Brown AC et al. Murine models of infectious exacerbations of airway inflammation. Curr Opin Pharmacol 2013; 13: 337–344.
116. Chambers DC, Gellatly SL, Hugenholtz P, Hansbro PM. JTD special edition ‘Hot Topics in COPD’—The microbiome in COPD. J Thorac Dis 2014; 6: 1525–1531.
117. Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. Expert Opin Drug Discov 2014; 9: 629–645.
118. Hansbro PM, Hamilton MJ, Fricker M, Gellatly SL, Jarnicki AG, Zheng D et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis. J Biol Chem 2014; 289: 18214–18227.
119. Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D et al. The nucleotidebinding domain, leucine-rich repeat protein 3 inflammasome/IL-1 receptor I axis mediates innate, but not adaptive, immune responses after exposure to particulate matter under 10 μm. Am J Resp Cell Mol Biol 2015; 52: 96–105.
120. Prieto-García A, Zheng D, Adachi R, Xing W, Lane WS, Chung K et al. Mast cell restricted mouse and human tryptase· heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen. J Biol Chem 2012; 287: 7834–7844.
121. Rehaume LM, Mondot S, Aguirre de Cárcer D, Velasco J, Benham H, Hasnain SZ et al. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and Ileitis in SKG mice. Arthritis Rheum 2014; 66: 2780–2792.